Our Stocks to Watch today include SpongeTech Delivery Systems, Inc. (OTCBB: SPNG), AmeriResource Technologies, Inc. (OTCBB: ARRT), VoIP, Inc. (OTCBB: VOIC), IDM Pharma, Inc. (NASD: IDMI)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts.
SPONGETECH DELIVERY SYSTEMS (OTCBB: SPNG)
Detailed Quote: http://www.otcpicks.com/quotes/SPNG.php
Company Profile: http://www.otcpicks.com/spongetech/spongetech.htm
SpongeTech Delivery Systems is a development stage company which designs, produces, markets and distributes cleaning products for vehicular use utilizing patented technology relating to sponges containing hydrophilic (liquid absorbing) foam polyurethane matrices. The Company's sponges are specially configured with an outer contact layer and an inner matrix, which is loaded with specially formulated soaps and wax that are released when the sponge is applied to a surface with minimal pressure. The Company's products are currently designed specifically for vehicular cleaning use. However, the Company is exploring the possibility of using its patented technology for the development of sponges for other uses, including for use with anti-bacterial, bath and kitchen soaps for household uses, as well as for use as a children's bath foam sponge.
SPNG News:
February 5 - SpongeTech Delivery Systems Updating the Company's Ecommerce Web Site
SpongeTech Web Site Update Incorporates New Products, a new Investor Relations Section and Updated Graphics
SpongeTech Delivery Systems, Inc. (OTCBB: SPNG) is actively working on updating the company's ecommerce Web site. The company is branching out beyond the car care industry, recently announcing the new Puddle Pals children's bath product and, just this past week, announcing its new Pet Sponge product family. The newly enhanced SpongeTech web site will incorporate new product information; an updated online ordering section for consumers to place product orders; a new investor relations section with recent company news, stock quotes, and IR contact information and it will also incorporate newly updated web site graphics.
SpongeTech COO Steven Moskowitz commented, "We are diligently working to update the company's web site and will be launching it in the near future. SpongeTech's web site has been a vital part of the company's expansion and growth in 2007. We have taken many product orders on the site, and it has been the hub of our expanding marketing activities. As we grow and add new products, we also need to expand the web site and bring up to date with the new products we are offering and the new markets we are pursuing. We also hope to provide more information on the web site for SpongeTech investors to keep them better informed about SpongeTech's activities and successes. Exciting things are happening at SpongeTech and we want to communicate professionally to our customers and investors through our web site."
For more information please contact Investor Relations at 1-877-SPONGE T for Bill Young or visit the company Web site at http://www.spongetech.com/.
AMERIRESOURCE TECHNOLOGIES (OTCBB: ARRT)
"Up 75.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ARRT.php
AmeriResource Technologies, Inc., through its subsidiaries, operates online auction drop-off locations that enables online sale of goods on eBay. As of March 31, 2007, the company operated 8 drop-off locations, as well as 25 affiliate locations. It also develops self-serve/checkout systems that enable customers of fast-food and take-out restaurants to place their food and beverage orders and pay with cash or a credit/debit card; and provides software design and product development for commercial business users doing business on eBay. The company also provides eBay liquidation services for excess inventory, overstock items, and merchandise that has been returned to the retailer; and conducts sales on eBay for the customers. In addition, it provides voice over Internet protocol (IP) communications solutions and IP communications devices. The company was incorporated in 1989 and is based in Las Vegas, Nevada.
ARRT News:
February 4 - AmeriResource Update: BizAuctions Revenues for January 2008 Increase by 335%
AmeriResource Technologies, Inc. (OTCBB: ARRT), a diversified holding company, announced that January revenues (unaudited) for its subsidiary, BizAuctions, Inc., increased by approximately 335% over revenues for the same period in 2007.
"For the month ending January 31, 2008, revenues (unaudited) have increased to approximately $386,495 from approximately $88,844, an increase of $297,651 or 335% over the corresponding month in 2007. BizAuctions' eBay business model continues to demonstrate strong and steady growth while the Company broadens its operations. Management has made great strides in increasing gross profits while reducing monthly operating expenses and has not realized net profits on a consistent basis," comments Delmar Janovec, CEO of AmeriResource.
"BizAuctions employs two primary business models, whereby it liquidates inventory through eBay on consignment for a lucrative commission; and/or it purchases inventory at a fraction of retail price for the purpose of liquidating it for a profit. BizAuctions consigns, buys inventory, and liquidates through eBay," continues Janovec.
BizAuctions' clients have included some of the Nation's leading retail names at the forefront of their industries. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate excess inventory on eBay.
BizAuctions' operations are designed for maximum capacity to handle most any eBay liquidation project. Whether the client is a Fortune 500 company with 1,000 items or a small business with 100 items, BizAuctions can take on most any project and recover funds from clients' excess inventory.
More information is available at www.BizAuctions.com. Investors and media can receive a free investor kit for BizAuctions, Inc. by contacting Investor Relations at investors@BizAuctions.com or (800) 961-3275. A virtual tour of BizAuctions' facilities and flash video presentation can be viewed at www.bizauctions.com/tour.shtml.
The Company encourages the public to read the above information in conjunction with its year-end 10-KSB for December 31, 2006, and the third Quarter 10-QSB for September 30, 2007. The financial statements can be viewed at www.sec.gov.
VOIP INCORPORATED (OTCBB: VOIC)
"Up 2.04% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/VOIC.php
VoIP, Inc. provides wholesale long-distance and local telephone services through its VoIP network. The company's telecommunication services include consumer and wholesale telecommunication services provided through its proprietary VOIP network and technology. Its products include EasyTalk, an automated number identification retail product, which is a long distance service marketed through its Website; RocketVoIP, a retail product that allows customers to use their high speed Internet connection to place local, long distance, and international calls through a media terminal adapter provided by it. The company serves competitive local exchange carriers, interexchange carriers, Internet service providers, cable operators, and VoIP service providers worldwide. VOIP, Inc. was founded in 1988. It was formerly known as Millennia Tea Masters, Inc. and changed its name to VoIP, Inc. in 2004. The company is headquartered in Altamonte Springs, Florida with an additional office in Dallas, Texas.
VOIC News:
February 5 - VoIP, Inc. Launches 'RazrClick,' the Patented Pay-Per-Click Advertising
VoIP, Inc. (OTCBB: VOIC), a global provider of advanced patented Voice Over Internet Protocol (VoIP) communications and services, announced today that it has launched “RazrClick,” a PPC (Pay Per Call) advertisement network utilizing our proprietor patents. Recently Google Inc. (NASD: GOOG) and eBay Inc. (NASD: EBAY) announced a multi-year agreement to benefit both companies. The agreement included components involving "click-to-call" advertising functionality.
RazrClick will focus strictly on gaining market share in the rapidly growing Pay-Per-Call advertising market. When you dissect the current Pay-Per-Click market and understand how many clicks it takes to actually gain a customer and compare that to the data surrounding Pay-Per-Call, it seems to be a no brainer that this technology is here to stay and is rapidly growing.
Pay-Per-Call is just getting started, but the research firm Kelsey Group says Pay-Per-Call ad revenue in the U.S. in 2009 will top $4 billion. By comparison, all paid search ad revenue in the U.S. surpassed $4 billion in the first half of this year and is growing at more than a 40% per year clip.
With Pay-Per-Call, advertisers get the power of the Web while still connecting with customers on the phone. There is a tremendous appetite amongst advertisers to buy phone calls in order to reach these consumers who are searching for products. Online advertisers pay on average $8 to $10 per call made via a Pay-Per-Call and that is up to six times higher than they might pay for a typical Pay-Per-Click ad.
“There are many companies that are providing Pay-Per-Click advertising. However, after careful research and consulting with attorneys we believe we have the only patent in this space,” stated Anthony Cataldo, CEO VoIP, Inc. “We intend to aggressively pursue all infringers so that our shareholders can reap the benefit of the value this patent affords the company; additionally we believe that all providers of this type of advertising/technology are directly violating our patents.”
IDM PHARMACEUTICALS INCORPORATED (NASD: IDMI)
"Up 66.67% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/IDMI.php
IDM Pharma, Inc., a biopharmaceutical company, engages in the development of products to treat and control cancer. The company primarily develops product candidates to destroy residual cancer cells, as well as product candidates to stimulate an immune response and prevent tumor recurrence. Its products include Junovan, an immune system stimulant, which completed phase III study for the treatment of osteosarcoma; Bexidem, a cell-based immunotherapeutic, which is in phase II trials for the treatment of bladder cancer; and Uvidem, which is in Phase II clinical trials for the treatment of melanoma, consists of dendritophages and melanoma tumor cell lysates. The company's products also include EP-2101, which has multiple tumor-associated CTL epitopes, is in Phase II trials for the treatment of non-small cell lung cancer; and Collidem, which is in Phase I/II trails for the treatment of Colorectal cancer, consists of dendritophages and tumor associated antigen peptides. It operates in the United States and France. IDM Pharma has collaboration agreements with sanofi-aventis S.A; Medarex, Inc.; GenPharm International, Inc.; Novartis; and Biotecnol S.A. The company is based in Irvine, California.
IDMI News:
February 4 - IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Children's Oncology Group Report Shows the Addition of L-MTP-PE to Chemotherapy Reduced the Risk of Death by 30% in Osteosarcoma Patients
IDM Pharma, Inc. (NASD: IDMI) announced the Journal of Clinical Oncology (JCO) has published findings from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133), entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report from the Children's Oncology Group." The landmark clinical trial, which is the largest study completed in this disease was a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG).
The COG's findings were based on long-term follow up of 662 patients with newly diagnosed non-metastatic osteosarcoma treated in the Phase 3 trial and demonstrated that the addition of L-MTP-PE to chemotherapy following surgery resulted in statistically superior Overall Survival (OS) the first stated aim of the study.
In the past two decades, there have been no treatment advances for patients with osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
"L-MTP-PE in combination with chemotherapy has demonstrated a significant long-term overall survival advantage in the largest Phase 3 clinical trial completed in patients with osteosarcoma," said Dr. Paul Meyers, vice chair, department of pediatrics at Memorial Sloan-Kettering Cancer Center and principal investigator of the Phase 3 trial. "These results are encouraging for children and young adults with osteosarcoma, considering the lack of progress for these patients in the last 20 years."
The JCO publication highlighting long-term follow up from this study formed the basis of the recent oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), regarding the Marketing Authorization Application (MAA) for L-MTP-PE for the treatment of patients with non-metastatic, resectable osteosarcoma. Updated results from this study were previously presented at the Connective Tissue Oncology Society (CTOS) annual meeting in November 2007. In addition, the new JCO publication highlights the long-term OS data whereas a prior JCO publication in 2005 focused on an Event Free Survival (EFS) additional analysis.
"These findings of statistically superior overall survival in long-term patient follow-up validate the survival benefit offered by L-MTP-PE and underscore the desperate need for new treatments for osteosarcoma patients," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We believe these findings were critical to the recent opinion from the Committee for Medicinal Products for Human Use in Europe and are a positive step toward bringing this important treatment to the European market and potentially gaining approval in the United States."
Study design and findings:
The multicenter, open label, randomized, factorial, four parallel treatment group Phase 3 study was designed to evaluate the effects of patient outcome of the addition of L-MTP-PE to three-drug chemotherapy (cisplatin, doxorubicin, and methotrexate) or four-drug-chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide) in patients with newly diagnosed resectable osteosarcoma without metastatic disease.
Patients received one of four prospectively randomized treatments and all patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2x2 factorial design.
In the published analysis, the chemotherapy regimens without L-MTP-PE resulted in similar OS and EFS. Overall Survival after six years of follow-up in patients treated with chemotherapy and L-MTP-PE was 78%, compared to 70% in patients treated only with chemotherapy (p=0.03). The addition of L-MTP-PE to chemotherapy resulted in approximately 30% decrease in the risk of death. EFS, an additional analysis which includes the occurrence of secondary malignancies, after six years of follow-up in patients treated with chemotherapy and L-MTP-PE was 67% compared to 61% in patients treated only with chemotherapy (p=0.08).
Treatment with L-MTP-PE was generally well tolerated in all phases of study. Adverse events were mild to moderate in severity and included chills, fever, nausea, vomiting, myalgia, headache, tachycardia (fast heart rate), hypo- and hypertension, fatigue and shortness of breath, all of which are consistent events with the activation of monocytes and macrophages by L-MTP-PE and the flu-like symptoms that follow cytokine release. These side effects are readily prevented or treated with acetaminophen.
L-MTP-PE Regulatory Status:
The Company recently announced that following presentation of data at an oral explanation hearing before the CHMP, the Committee determined in a non-binding opinion that L-MTPE-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock stop, or time extension. The clock stop will allow the Company additional time to respond to all the remaining questions regarding the MAA.
The CHMP has requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company is required to address a number of remaining questions relating to chemistry, manufacturing and controls (CMC). The Company now expects to receive a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008.
L-MTP-PE was granted orphan drug status in Europe in 2004. The MAA for L-MTP-PE was submitted to the EMEA and accepted for review in November 2006.
As previously announced, in the United States the Company continues to work with COG as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE conducted by COG and to respond to other questions in the not approvable letter the Company received from the U.S. Food and Drug Administration (FDA).
L-MTP-PE was granted orphan drug status in the United States in 2001. The new drug application (NDA) for L-MTP-PE was submitted to FDA in October 2006 and was accepted for review in December 2006.
ABOUT OSTEOSARCOMA
About 3 percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.
Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the U.S. each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated seventeen thousand dollars by the company and four hundred thousand free trading shares by a non-controlling third party for multiple 30-day SPNG IR programs. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
